

# Nita Ahuja

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1577743/publications.pdf>

Version: 2024-02-01

59  
papers

2,712  
citations

218592

26  
h-index

182361

51  
g-index

59  
all docs

59  
docs citations

59  
times ranked

5255  
citing authors

#	ARTICLE	IF	CITATIONS
1	A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. <i>Clinical Epigenetics</i> , 2021, 13, 25.	1.8	11
2	Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. <i>JCI Insight</i> , 2020, 5, .	2.3	22
3	Variations in recommended surveillance in colorectal cancer survivorship care plans.. <i>Journal of Clinical Oncology</i> , 2020, 38, 13-13.	0.8	4
4	A phase 1 trial of the oral DNA methyltransferase inhibitor CCâ€486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. <i>Cancer</i> , 2019, 125, 2837-2845.	2.0	17
5	Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. <i>Clinical Epigenetics</i> , 2019, 11, 59.	1.8	106
6	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019, 25, 2664-2671.	3.2	80
7	Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and BrafV600E-Induced Tumorigenesis. <i>Cancer Cell</i> , 2019, 35, 315-328.e6.	7.7	107
8	Trends in Outcomes After Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy. <i>Journal of Surgical Research</i> , 2019, 234, 240-248.	0.8	14
9	Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 591-591.	0.8	6
10	DNA Methylation Patterns Separate Senescence from Transformation Potential and Indicate Cancer Risk. <i>Cancer Cell</i> , 2018, 33, 309-321.e5.	7.7	84
11	Extraskeletal versus Skeletal Ewing Sarcoma in the adult population: Controversies in care. <i>Surgical Oncology</i> , 2018, 27, 373-379.	0.8	32
12	A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. <i>Clinical Cancer Research</i> , 2018, 24, 6160-6167.	3.2	46
13	Minimally Invasive Versus Open Primary Resection for Retroperitoneal Soft Tissue Sarcoma: A Propensity-Matched Study From the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2018, 25, 2209-2217.	0.7	13
14	Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma. <i>Oncotarget</i> , 2018, 9, 19379-19395.	0.8	13
15	Locally advanced primary recto-sigmoid cancers: Improved survival with multivisceral resection. <i>American Journal of Surgery</i> , 2017, 214, 432-436.	0.9	4
16	Postoperative complications following intraoperative radiotherapy in abdominopelvic malignancy: A single institution analysis of 113 consecutive patients. <i>Journal of Surgical Oncology</i> , 2017, 115, 883-890.	0.8	5
17	Epigenetic therapy and chemosensitization in solid malignancy. <i>Cancer Treatment Reviews</i> , 2017, 55, 200-208.	3.4	33
18	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. <i>Clinical Cancer Research</i> , 2017, 23, 2691-2701.	3.2	106

#	ARTICLE	IF	CITATIONS
19	The independent effect of cancer on outcomes: a potential limitation of surgical risk prediction. <i>Journal of Surgical Research</i> , 2017, 220, 402-409.e6.	0.8	16
20	High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 191-199.	0.2	4
21	Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 1552-1562.	1.3	19
22	Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?. <i>Journal of Surgical Oncology</i> , 2017, 115, 351-357.	0.8	35
23	Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. <i>PLoS ONE</i> , 2017, 12, e0176139.	1.1	30
24	Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. <i>PLoS ONE</i> , 2017, 12, e0179501.	1.1	79
25	Epigenetically altered miR-1247 functions as a tumor suppressor in pancreatic cancer. <i>Oncotarget</i> , 2017, 8, 26600-26612.	0.8	24
26	Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma. <i>PLoS ONE</i> , 2016, 11, e0162929.	1.1	7
27	Long-term outcomes in treatment of retroperitoneal sarcomas: A 15 year single-institution evaluation of prognostic features. <i>Journal of Surgical Oncology</i> , 2016, 114, 56-64.	0.8	41
28	A Contemporary Evaluation of the Cause of Death and Long-Term Quality of Life After Total Pancreatectomy. <i>World Journal of Surgery</i> , 2016, 40, 2513-2518.	0.8	28
29	Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. <i>Hpb</i> , 2016, 18, 236-246.	0.1	79
30	Predictors of improved survival for patients with retroperitoneal sarcoma. <i>Surgery</i> , 2016, 160, 1628-1635.	1.0	28
31	Understanding the Barriers to Hiring and Promoting Women in Surgical Subspecialties. <i>Journal of the American College of Surgeons</i> , 2016, 223, 387-398.e2.	0.2	66
32	Epigenetic Therapeutics: A New Weapon in the War Against Cancer. <i>Annual Review of Medicine</i> , 2016, 67, 73-89.	5.0	285
33	Combining Epigenetic and Immunotherapy to Combat Cancer. <i>Cancer Research</i> , 2016, 76, 1683-1689.	0.4	251
34	Time to Chemotherapy After Abdominoperineal Resection: Comparison Between Primary Closure and Perineal Flap Reconstruction. <i>World Journal of Surgery</i> , 2016, 40, 225-230.	0.8	10
35	Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients. <i>Oncotarget</i> , 2016, 7, 86480-86489.	0.8	15
36	Epigenetic priming prior to pembrolizumab in microsatellite-stable (MSS) advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3626-TPS3626.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Passive hyperspectral sensing to identify colorectal cancer in intraoperative colon specimens.. Journal of Clinical Oncology, 2016, 34, e151161-e151161.	0.8	0
38	Tracking Early Readmission After Pancreatectomy to Index and Nonindex Institutions. JAMA Surgery, 2015, 150, 152.	2.2	39
39	Early hospital readmission for gastrointestinal-related complications predicts long-term mortality after pancreatectomy. American Journal of Surgery, 2015, 210, 636-642.e1.	0.9	9
40	Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience. Clinical Genitourinary Cancer, 2015, 13, 435-440.	0.9	12
41	Promoter Methylation of <i>CDO1</i> Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome. Clinical Cancer Research, 2015, 21, 3492-3500.	3.2	50
42	Personalized Approaches to Gastrointestinal Cancers. Surgical Clinics of North America, 2015, 95, 1081-1094.	0.5	5
43	Early detection of pancreatic cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 321-31.	0.7	29
44	A phase I study of investigational agent SGI-110 combined with irinotecan in previously treated metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2015, 33, TPS797-TPS797.	0.8	1
45	A phase I trial of oral 5-azacitidine in combination with romidepsin in advanced solid tumors with an expansion cohort in virally mediated cancers and liposarcoma.. Journal of Clinical Oncology, 2015, 33, TPS2619-TPS2619.	0.8	0
46	A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence.. Journal of Clinical Oncology, 2015, 33, TPS4144-TPS4144.	0.8	0
47	Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget, 2014, 5, 587-598.	0.8	367
48	CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas. Epigenetics, 2014, 9, 738-746.	1.3	7
49	Assessing the experience in complex hepatopancreatobiliary surgery among graduating chief residents: Is the operative experience enough?. Surgery, 2014, 156, 385-393.	1.0	39
50	Race-based differences in length of stay among patients undergoing pancreatoduodenectomy. Surgery, 2014, 156, 528-537.	1.0	14
51	A comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the nationwide inpatient sample. Surgery, 2014, 156, 538-547.	1.0	60
52	Inpatient survival after gastrectomy for gastric cancer in the 21st century. Journal of Surgical Research, 2014, 190, 72-78.	0.8	5
53	Is Minimally Invasive Colon Resection Better Than Traditional Approaches?. JAMA Surgery, 2014, 149, 177.	2.2	119
54	Overcoming immune system evasion by personalized immunotherapy. Personalized Medicine, 2014, 11, 561-564.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer.. Journal of Clinical Oncology, 2014, 32, 569-569.	0.8	3
56	Prognostic factors after pancreaticoduodenectomy for duodenal adenocarcinoma: Results from a dual center analysis.. Journal of Clinical Oncology, 2014, 32, e15181-e15181.	0.8	0
57	Association of recurrence patterns following resection of pancreatic adenocarcinoma with overall survival.. Journal of Clinical Oncology, 2014, 32, 4127-4127.	0.8	2
58	Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene, 1999, 18, 3284-3289.	2.6	156
59	Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene, 1998, 16, 3197-3202.	2.6	74